EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W ...
Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, ...
Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference, ...
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
Sanofi is halting the phase 3 MOBILIZE trial evaluating riliprubart for chronic inflammatory demyelinating polyneuropathy due to lack of efficacy.
Creative Biolabs has expanded its complement testing capabilities to help researchers overcome challenges in complement drug development through comprehensive complement activity assays, CH50 ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results